

*From Search & Review
to Organisation Impact:*
**Building Trusted
Evidence Workflows
with DistillerSR
& Elsevier**

April 22, 2026

Elliott Parris, *MSci*
Advanced Data Solutions
Manager, EMEA




Advancing human progress together

Advancing human
progress *together*



ELSEVIER

Systematic literature search: the backbone of science & our roles



ELSEVIER

Embase

- Over 49 million records, indexed on full text
- Over 8,500 journals including 3k not contained in MEDLINE®
- Over 5.5 million conference abstracts from 2009 to present

ScienceDirect

- 23m Articles & book chapters
- 39% Elsevier citation share of cross-disciplinary, highly cited literature
- 3.8m Open Access articles

Datasets

- APIs
- Third Party Platform Usage Rights
- AI Reuse Rights

R&D pressures in 2025



\$190B

**R&D costs per
annum**



25%

of revenue



14+

**years median
launch time**

The promise of AI: unlocking information



71%

believe AI will have a transformative effect¹



98%


believe literature synthesis is the killer app¹



40%

capacity savings from Agentic AI²

There is building evidence that agentic AI may be able to help



In pharma, **75 - 85% of workflows contain tasks that could be enhanced or automated by AI agents**, potentially freeing up 25 to 40 percent of an organization's capacity



Up to **95% of life science roles may have agentic teammates**. Every functional area, domain, and job family has tasks for which agents could be deployed



[The] full potential of agents could give companies **incremental growth of 5 – 13%**

EBITDA would increase by 3.4 to 5.4% over the next three to five years

The AI paradox: 80% companies using AI, 80% report no benefit

95% of proprietary GenAI pilots fail ⁽¹⁾

Trust in data

- Trusted source
- Rights compliance
- Integration

Trust in technology

- Provenance
- Traceability
- Transparency

The AI trust gap

 **84%** using GenAI in R&D

 but only **22%** trusting it ⁽¹⁾

19.9% citations fabricated in GPT-4o lit reviews


29% in less familiar or specialised topics

45.4% “real” citations had bibliographic errors

2/3 of references **fabricated or inaccurate**

Source: *JMIR Mental Health*, Nov 2025 (DOI: [10.2196/80371](https://doi.org/10.2196/80371))

Top Cited Domains on LLMs (ChatGPT, Google AI Mode, Perplexity): October 2025



Based on a Semrush study of 230K prompts conducted in October 2025

Why general-purpose AI tools are not yet fit for R&D



Lack Transparency

- Black box, no citations¹
- Nearly 2 in 3 citations hallucinated or with errors²
- Satirical posts presented as legitimate sources¹
- **Retracted research** rated as ‘word-leading’³



Erodes critical thinking

- Inflated user trust, regardless of the accuracy¹
- Creating an **illusion of authoritativeness**¹
- Potential for sycophantic responses¹



Privacy & security issues

- Widespread use, 84% of corporate researchers use Gen AI tool⁵
- **User inputs being used to train models**
- Ensuring security, privacy and handling of confidential information

Responsible AI is Elsevier's number 1 priority



We consider the real-world impact of our solutions.



We take action to prevent the creation or reinforcement of unfair bias.



We can explain how our solutions work.




We create accountability through human oversight.





We respect privacy and champion robust data governance.


Two categories of use cases Elsevier supports with needed rights

Individual use


 reading


 browsing


 downloading*


 searching

Systematic use

 large scale downloads


 indexing


 extracting knowledge


 AI – RAG, model training


Two categories of use cases Elsevier supports with needed rights

Individual use

 reading

 browsing

 downloading*

 searching

Systematic use


 Speed to insight

 Empower researchers with AI

 High throughput at enterprise scale

Two categories of use cases Elsevier supports with needed rights


Platform products




Datasets



Data Available
via Multiple
Delivery
Mechanisms




Internal or 3rd party solution e.g. text data mining platforms, enterprise search platforms, literature review platforms, RAG applications, predictive models etc.




Systematic use-cases

Partnering as Your Trusted Advisors



- ✓ Multidisciplinary scientific literature
- ✓ Domain-specific data
- ✓ Cross-publisher abstracts and metadata
- ✓ Enrichment tools
- ✓ Semantic search
- ✓ Curated datasets
- ✓ Subject matter and data science experts
- ✓ Solution architecture and delivery design
- ✓ Integration support

Systematic literature search: the backbone of science & our roles



ELSEVIER

Embase

- Over 49 million records, indexed on full text
- Over 8,500 journals including 3k not contained in MEDLINE®
- Over 5.5 million conference abstracts from 2009 to present

ScienceDirect

- 23m Articles & book chapters
- 39% Elsevier citation share of cross-disciplinary, highly cited literature
- 3.8m Open Access articles

Datasets

- APIs
- Third Party Platform Usage Rights
- AI Reuse Rights

The result: an integrated DistillerSR & Elsevier workflow

Source:
Embase

Can use
Embase
PUI for
RefID
schema

Link to
Embase
Search
Help

Enter /
Paste
Embase
search
string

Embase
search
history



Full Legal Certainty
For AI Use Case(s)



AI Reuse of Elsevier
PDFs (e.g. via Doc Del)



Unified Search
Interface




Easy Initial Search
(Refinement On Embase)

ELSEVIER

DistillerSR

Critical biomedical insights can be missed due to expertise silos




What is the standard treatment for atherosclerosis?

- Perceived complexity of specialized databases can be a barrier for casual or novice users
- Building search queries can be time consuming even for experts
- Tool adoption might be low and restricted only to specialists

('atherosclerosis'/mj OR 'atherosclerosis':ti,ab,kw)
AND (('drug therapy'/lnk OR 'drug therapy'/de OR
'treat*':ti,ab,kw OR 'therap*':ti,ab,kw OR
'manage*':ti,ab,kw OR 'standard treatment':ti,ab,kw
OR 'current practice\$':ti,ab,kw OR 'recent
advancement\$':ti,ab,kw OR 'recent
develop*':ti,ab,kw OR 'new treatment\$':ti,ab,kw OR
'latest treatment\$':ti,ab,kw))

Easier access to biomedical insights with AI assisted searching



Embase AI helps more users access high-quality information



User-friendliness



Transparent searching



Trusted and up-to-date content



High security standards



What antiepileptic drug is best transported over the BBB?

Phenytoin and levetiracetam are transported by mouse P-gp but not human P-gp, while carbamazepine is not transported by P-gp.

Transport of Antiepileptic Drugs Over the Blood-Brain Barrier (BBB)

The transport of antiepileptic drugs (AEDs) is a critical factor in their efficacy, particularly in the context of the Blood-Brain Barrier (BBB).

In summary, the transport of AEDs over the BBB is influenced by various transporters, including P-gp and MCTs, with significant species and age-related differences. Phenytoin and levetiracetam show differential transport by P-gp in mice versus humans, while VPA can modulate P-gp function, potentially improving drug penetration in resistant epilepsy cases.

[Show all references >](#)



What are the most relevant transporters at the BBB for those drugs?

Conversational natural language queries and **concise content summaries** allow users of **all experience levels** to discover critical insights faster.

Embase AI makes the search process more transparent

What antiepileptic drug is best transported over the BBB?



User-friendliness



Transparent
searching



Trusted and up-to-
date content



High security
standards

✓ 1. Translating the question into Embase query language

Embase query:

```
('antiepileptic drug'/exp OR 'anticonvulsive agent'/exp OR 'antiepileptics':ti,ab,kw OR 'anticonvulsants':ti,ab,kw) AND ('blood brain barrier'/exp OR 'bbb':ti,ab,kw OR ('blood' NEAR/3 'brain' NEAR/3 'barriers$'):ti,ab,kw) AND ('best':ti,ab,kw OR 'optimal':ti,ab,kw OR 'most effective':ti,ab,kw OR 'most efficient':ti,ab,kw OR 'transports':ti,ab,kw OR 'cross$':ti,ab,kw)
```





[Open in results page](#) ↗

[Copy query](#) 📄

Auto-generated Embase syntax

- Helps understand exactly how the search was interpreted
- **Supports novice or casual users** become better searchers
- Can serve as a valuable starting point for constructing comprehensive queries to use in Embase.com

Support informed decisions with verifiable responses

-  User-friendliness
-  Transparent searching
-  Trusted and up-to-date content
-  High security standards



role in the distribution of AEDs. Studies have shown that phenytoin and levetiracetam are transported by mouse Pgp but not by human Pgp, while carbamazepine is not transported by Pgp at all [1]. Lamotrigine, on the other

References:

1. Article • Embase, MEDLINE
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein
Bahes S., Gastens A.M., Fedorowitz M., Potocká H., Kaever V., Löscher W.
Neuropharmacology 2007 52:2 (333-346)
[Abstract](#) [Index terms](#) [Full text](#) [Link text](#) [Similar records](#)

In view of the important role of P-glycoprotein (Pgp) and other drug efflux transporters for drug distribution and resistance, the identification of compounds as substrates of Pgp-mediated transport is one of the key issues in drug discovery and development, particularly for compounds acting on the central nervous system. To evaluate the role of Pgp in drug transport, various cell lines expressing human or mouse Pgp have been established. In particular, Pgp-transfected kidney cell lines are widely used to evaluate substrates or inhibitors. Furthermore, such cell lines are also used in combination with Pgp-transfected liver cell lines to evaluate substrates or inhibitors in vitro or in vivo models of the blood-brain barrier. The multidrug resistance protein (MRP) family of transporters is also involved in the transport of antiepileptic drugs (AEDs) in patients with drug resistance. In the present study, we investigated the transport of AEDs by Pgp or MRPs in the present MDCKII dog kidney or LLC-PK1 pig kidney cells transfected with human or mouse Pgp or MRP2 or mouse mdr1a and mdr1b sequences to measure the directional transport of AEDs. Cyclosporin A (CsA) and vinblastine were used as reference standards for Pgp and MRP2, respectively. The AEDs phenytoin and levetiracetam were directionally transported by Pgp and MRP2, respectively. The AEDs phenytoin and levetiracetam were directionally transported by Pgp and MRP2, respectively. Whereas CsA was transported by both types of Pgp, carbamazepine was not transported by any type of Pgp and did not inhibit the transport of CsA. In contrast to vinblastine, none of the AEDs was transported by MRP2 in transfected kidney cells. The data indicate that substrate recognition or transport efficacy by Pgp differs between human and mouse for certain AEDs. Such species differences, which are certainly not restricted to human and mouse, may explain, at least in part, the controversial data which have been previously reported for AED transport by Pgp in preparations from different species. However, because transport efficacy of efflux transporters such as Pgp or MRP2 may not only differ between species but also between tissues, the present data do not exclude that the AEDs examined are weak substrates of Pgp or MRP2 at the human BBB. © 2006 Elsevier Ltd. All rights reserved.



Drug terms

[anticonvulsive agent](#) [carbamazepine](#) [cyclosporine](#) [levetiracetam](#)

Embase AI supports user confidence through


- Responses based on the full Embase corpus of content, including **Emtree indexing**
- **In-line references** to evaluate validity of summaries
- **Daily content updates** to reflect latest research

A secure environment for confidential work



Embase AI **minimizes the risk** of compromising data privacy.

Embase AI: how it works & adds value to DistillerSR workflow




Embase AI: key benefits for your organization



**Empower
everyone**

Allow access to biomedical insights for users of **all experience levels**.



**Save
time**

Find insights faster and free up time for other important tasks.



**Minimize
risk**

Increase decision confidence with responses from trusted content.



**Protect
IP**

Rely on **high security standards** to keep your data private.

Embase AI's value: don't take our word for it, take our testers' word



... Improve workflow

“It would **help out enterprise users** more quickly find summary answers to basic medical queries.”

- Information Specialist,
Large Pharma



... Save time

“Embase AI **can save us >50% of the time** we spend answering physicians' questions.”

- Medical Affairs Manager,
Large Pharma




... Improve the quality and depth of research

“Embase AI is changing how I think about the problem, it helps me ask the right questions better. It **adds 100% of extra value** to Embase.”

- Product Manager,
Large MedTech

Systematic literature search: the backbone of science & our roles



ELSEVIER

Embase

- Over 49 million records, indexed on full text
- Over 8,500 journals including 3k not contained in MEDLINE®
- Over 5.5 million conference abstracts from 2009 to present


ScienceDirect

- 23m Articles & book chapters
- 39% Elsevier citation share of cross-disciplinary, highly cited literature
- 3.8m Open Access articles


Datasets

- APIs
- Third Party Platform Usage Rights
- AI Reuse Rights

Deploying generative AI across multiple workflows, content sets and reusing expert outputs to deliver more organisational impact



Systematic literature search: the backbone of science & our roles



ELSEVIER

Embase

- Over 49 million records, indexed on full text
- Over 8,500 journals including 3k not contained in MEDLINE®
- Over 5.5 million conference abstracts from 2009 to present



ScienceDirect

- 23m Articles & book chapters
- 39% Elsevier citation share of cross-disciplinary, highly cited literature
- 3.8m Open Access articles

Datasets

- APIs
- Third Party Platform Usage Rights
- AI Reuse Rights

Systematic literature reuse: the backbone of science & our roles



The next AI horizon for R&D



AI unlocks maximum value when you can trust the associated outcomes and reuse them

How could your data be reused with AI assistants to help solve faster the most complex and costly challenges in drug & device development?

Thank you

Learn more

+ **Monday's Presentation** – *From Pilot to Production: Building Trust in Agentic AI for Pharma R&D* – **Available Via The Link**

Talk more


Elliott Parris, Advanced Data Solutions Manager, EMEA

Inga Link-AI-Zadjali, Regional Account Director, North Europe



ELSEVIER

Let's talk
Book a meeting
via the link



Advancing human progress together